Peak Bio, Inc. (PKBOW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Peak Bio, Inc. (PKBOW) trades at $0.0099 with AI Score 38/100 (Grade D). Peak Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for oncology and inflammation. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for PKBOW: PKBOW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PKBOW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PKBOW: 3/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Peak Bio, Inc. (PKBOW) Healthcare & Pipeline Overview
Peak Bio, Inc. is a clinical-stage biopharmaceutical company developing novel ADC product candidates and small molecule therapeutics. Their lead candidate, PHP-303, targets the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company leverages its proprietary Thailanstatin technology to address unmet needs in oncology and inflammation.
What Is the Investment Thesis for PKBOW?
Peak Bio, Inc. presents a high-risk, high-reward investment opportunity characteristic of early-stage biopharmaceutical companies. The company's valuation is currently tied to the successful clinical development of its lead product candidates, PHP-303 and its ADC pipeline. The Phase II trial for PHP-303 in AATD represents a near-term catalyst; positive data could significantly increase the company's market capitalization. The development of novel ADC product candidates utilizing the Thailanstatin technology offers long-term growth potential in the oncology space. However, the company's small size and limited financial resources introduce significant execution risk. Investors should closely monitor clinical trial outcomes, regulatory milestones, and the company's ability to secure additional funding.
Based on FMP financials and quantitative analysis
PKBOW Key Highlights
Peak Bio, Inc. is a clinical-stage biopharmaceutical company focused on oncology and inflammation.
- Lead product candidate PHP-303 is a small molecule awaiting Phase II clinical study for Alpha1 anti-trypsin deficiency (AATD).
- Proprietary toxin PH-1 (Thailanstatin) is being used to develop novel ADC product candidates.
- The company has a market capitalization of $0.00B as of 2026-03-17.
- The company employs 6 individuals.
Who Are PKBOW's Competitors?
PKBOW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CELU Celularity Inc. | $0.77 | -1.41% | $22.2M | — |
| LIXT Lixte Biotechnology Holdings, Inc. | $7.21 | -6.00% | $89.1M | 56 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PKBOW's Key Strengths?
Proprietary Thailanstatin technology platform.
- Lead product candidate PHP-303 targeting a rare disease.
- Experienced management team with expertise in drug development.
- Focus on unmet medical needs in oncology and inflammation.
What Are PKBOW's Weaknesses?
Limited financial resources.
- Small size and limited infrastructure.
- Dependence on successful clinical trial outcomes.
- Early-stage development pipeline.
What Could Drive PKBOW Stock Higher?
Phase II clinical trial results for PHP-303 in Alpha1 anti-trypsin deficiency (AATD).
- Development and advancement of ADC pipeline for oncology indications.
- Potential strategic partnerships and licensing agreements.
- Pursuit of orphan drug designation for PHP-303.
What Are the Key Risks for PKBOW?
Negative return on equity (-11.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for PHP-303 or ADC candidates.
- Regulatory delays or rejection of drug applications.
- Competition from other biotechnology companies.
- Patent challenges and intellectual property disputes.
- Limited financial resources and dependence on additional funding.
What Are the Growth Opportunities for PKBOW?
- Advancement of PHP-303 in AATD: The successful completion of the Phase II clinical trial for PHP-303 in Alpha1 anti-trypsin deficiency (AATD) represents a significant growth opportunity. The AATD market is estimated to reach $1.7 billion by 2028, driven by increasing diagnosis rates and the need for effective therapies. Positive clinical data could lead to accelerated regulatory approval and commercialization, providing Peak Bio with a valuable revenue stream. The timeline for Phase II completion is projected within the next 12-18 months.
- Development of ADC Pipeline: Peak Bio's proprietary Thailanstatin technology offers a platform for developing novel Antibody-Drug Conjugates (ADCs) for various cancer indications. The global ADC market is projected to reach $29.4 billion by 2030, fueled by the increasing demand for targeted cancer therapies. Successful development and clinical validation of ADC candidates could position Peak Bio as a key player in the oncology space. This growth is expected to materialize over the next 3-5 years as candidates progress through preclinical and clinical stages.
- Strategic Partnerships and Licensing Agreements: Peak Bio can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Licensing agreements for its Thailanstatin technology could also generate significant revenue. These partnerships can provide financial resources and expertise to advance the company's pipeline. Such opportunities could arise within the next 1-2 years as the company seeks to expand its reach and capabilities.
- Expansion into New Therapeutic Areas: While currently focused on oncology and inflammation, Peak Bio could expand its research and development efforts into other therapeutic areas with unmet medical needs. This diversification could mitigate risk and create new growth opportunities. The company could leverage its existing technology platform and expertise to develop therapies for other diseases. This expansion could begin within the next 2-3 years as the company evaluates new market opportunities.
- Orphan Drug Designation and Regulatory Exclusivity: Securing orphan drug designation for PHP-303 in AATD and other potential indications can provide significant market exclusivity and regulatory benefits. Orphan drug designation can lead to faster regulatory review and approval, as well as extended market exclusivity. This can provide a competitive advantage and protect the company's investment in developing therapies for rare diseases. The company is actively pursuing orphan drug designation for its lead candidate.
What Are PKBOW's Competitive Advantages?
- Proprietary Thailanstatin technology platform for developing novel ADC product candidates.
- Patent protection for its drug candidates and technologies.
- Focus on orphan diseases with limited treatment options.
- Expertise in spliceosome modulation and ADC development.
What Does PKBOW Do?
Peak Bio, Inc., headquartered in Palo Alto, California, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutics for oncology and inflammation. The company was founded with the goal of addressing significant unmet medical needs in these areas. Peak Bio's core technology revolves around its proprietary toxin, PH-1, also known as Thailanstatin, a spliceosome modulator. This unique compound is being utilized to generate a pipeline of novel Antibody-Drug Conjugate (ADC) product candidates aimed at improving outcomes for cancer patients. The company's lead product candidate, PHP-303, is a small molecule currently advancing towards a Phase II dose clinical study. PHP-303 is specifically designed to treat Alpha1 anti-trypsin deficiency (AATD), a rare genetic disorder. Peak Bio's focus on both oncology and rare diseases highlights its commitment to developing targeted therapies for patient populations with limited treatment options. The company's strategic approach involves leveraging its proprietary technology platform and advancing promising drug candidates through clinical development to ultimately bring new and effective treatments to market. With a small team of 6 employees, Peak Bio is focused on efficient drug development.
What Products and Services Does PKBOW Offer?
- Develops therapeutics for oncology and inflammation.
- Utilizes proprietary Thailanstatin technology to create novel ADC product candidates.
- Focuses on addressing unmet needs in cancer patients.
- Advances PHP-303, a small molecule, for the treatment of Alpha1 anti-trypsin deficiency (AATD).
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks strategic partnerships to accelerate development and commercialization.
How Does PKBOW Make Money?
- Develops and patents novel therapeutic compounds.
- Out-licenses or partners with larger pharmaceutical companies for late-stage development and commercialization.
- Generates revenue through milestone payments, royalties on sales of approved products, and licensing fees.
What Industry Does PKBOW Operate In?
The biotechnology industry is characterized by high R&D spending, long development timelines, and significant regulatory hurdles. Companies like Peak Bio, Inc. operate in a competitive landscape with both large pharmaceutical companies and other smaller biotech firms. The development of novel therapeutics for oncology and rare diseases is a key area of focus within the industry, driven by unmet medical needs and the potential for high returns on investment. The success of companies like Peak Bio depends on their ability to innovate, secure funding, and navigate the complex regulatory environment.
Who Are PKBOW's Key Customers?
- Patients suffering from cancer and inflammatory diseases.
- Pharmaceutical companies seeking to in-license or acquire novel therapeutic candidates.
- Healthcare providers who prescribe and administer the company's products.
How Peak Bio, Inc. Is Valued
Relative to its peer group, PKBOW's quantitative score of 38/100 is below the peer average of 72/100.
Company Profile
Peak Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Palo Alto, US. The company is led by CEO Hoyoung Huh. PKBOW has traded publicly since 2022.
Key Financial Metrics
Return on equity for Peak Bio, Inc. stands at -11.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 21.48 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -31.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Peak Bio, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
PKBOW Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Peak Bio's future, indicating that those closest to the company believe in its potential.
- Positive community sentiment has been building around Peak Bio's innovative therapeutic pipeline, with discussions highlighting its unique approach to treatment.
- Analysts have noted increased interest in Peak Bio's recent clinical trials, suggesting that the market is optimistic about upcoming results.
- The company's strategic partnerships have garnered attention, enhancing its credibility and expanding its reach in the biotech sector.
Bear Case
- Concerns over regulatory hurdles have surfaced, with some investors wary of the potential delays in bringing products to market.
- Recent discussions in the community reflect skepticism about the company's ability to secure necessary funding for ongoing projects.
- Market perception has been clouded by broader economic uncertainties, leading to increased caution among investors in the biotech space.
- Some analysts have pointed out that Peak Bio's competitive landscape is intensifying, which could impact its market position and growth potential.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PKBOW Latest News
No recent news available for PKBOW.
PKBOW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PKBOW.
Price Targets
Wall Street price target analysis for PKBOW.
PKBOW MoonshotScore
What does this score mean?
The MoonshotScore rates PKBOW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Hoyoung Huh
CEO
Hoyoung Huh is the CEO of Peak Bio, Inc. He has extensive experience in the biopharmaceutical industry, with a background in leading and managing drug development programs. His career includes roles in various biotech companies, focusing on oncology and other therapeutic areas. He brings a wealth of knowledge in clinical development, regulatory affairs, and commercialization strategies. He is responsible for guiding Peak Bio's strategic direction and overseeing the advancement of its product pipeline.
Track Record: Under Hoyoung Huh's leadership, Peak Bio has focused on advancing PHP-303 into Phase II clinical trials and developing its ADC pipeline. He has overseen the company's efforts to secure funding and build strategic partnerships. His leadership has been instrumental in driving the company's growth and achieving key milestones in its drug development programs. He manages a small team of 6 employees.
What Investors Ask About Peak Bio, Inc. (PKBOW) — Healthcare
What does the AI Score mean for PKBOW?
PKBOW holds an AI Score of 38/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Peak Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for oncology and inflammation. Their lead product candidate, PHP-303, is undergoing Phase II …
What does Peak Bio, Inc. do?
Peak Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for oncology and inflammation. The company's primary focus is on advancing its lead product candidate, PHP-303, a small molecule in Phase II clinical trials for Alpha1 anti-trypsin deficiency (AATD), a rare genetic disorder.
What are the main risks for PKBOW?
The main risks for Peak Bio, Inc. include clinical trial failures, regulatory hurdles, competition from other biotechnology companies, patent challenges, and limited financial resources. Clinical trial failures for PHP-303 or its ADC candidates could significantly impact the company's valuation and future prospects. Regulatory delays or rejection of drug applications could also impede the company's progress.
How does Peak Bio, Inc. manage patent expiration risks?
As a clinical-stage biopharmaceutical company, Peak Bio, Inc. actively manages patent expiration risks through a multi-faceted approach. This includes continuously monitoring the competitive landscape for potential patent infringements and actively defending its intellectual property rights. The company also focuses on developing new formulations and delivery methods for its existing drugs to extend their market exclusivity.
What revenue streams does Peak Bio, Inc. have in healthcare?
Currently, as a clinical-stage biopharmaceutical company, Peak Bio, Inc. does not have any commercialized products and therefore does not generate revenue from product sales. The company's potential future revenue streams are contingent upon the successful development, regulatory approval, and commercialization of its drug candidates.
What are the key factors to evaluate for PKBOW?
Peak Bio, Inc. (PKBOW) holds an AI score of 38/100 (low). presents a high-risk, high-reward investment opportunity characteristic of early-stage biopharmaceutical companies. Not financial advice.
How frequently does PKBOW data refresh on this page?
PKBOW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PKBOW's recent stock price performance?
Peak Bio, Inc. (PKBOW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Thailanstatin technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PKBOW overvalued or undervalued right now?
Peak Bio, Inc. (PKBOW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data.
- AI analysis is pending and may provide further insights.